Instead, when targeted DNA/RNA next-generation sequencing is employed, KMT2A could be included in the panel and prioritized in non-AITL PTCL-NOS or TFH-negative/ambiguous phenotypes and in patients with high-risk clinical features. This evidence concerns the gene KMT2A and angioimmunoblastic T-cell lymphoma.